Last checked at LONDON MARKET PRE-OPEN: S&N CEO Departs; Candy Eyes Capital & Counties
LONDON MARKET PRE-OPEN: S&N CEO Departs; Candy Eyes Capital & Counties
21 Oct 19 07:42
- Home
- Share Prices
- AQSE Share Prices
- Share Chat
- FX
- News
- Blogs
- RNS
- Media
- Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News12
AZN Share
Chat25
AZN Share
Trades14,450
AZN
Live RNS1
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
AZN Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
6,980.00
Bid:
6,973.00
Ask:
6,976.00
Change:
35.00
(0.50%)
Spread:
3.00 (0.04%)
Open:
7,025.00
High:
7,075.00
Low:
6,944.00
Yest. Close:
6,945.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.21 Oct 19 07:42FDA approves AstraZeneca drug for heart failure risk
(Sharecast News) - AstraZeneca on Monday announced that its Farxiga treatment against heart failure risk in certain patient groups has received approval from the US Food and Drug Administration.
21 Oct 19 07:16UK Earnings, Trading Statements Calendar - Next 7 Days
UK Earnings, Trading Statements Calendar - Next 7 Days
17 Oct 19 16:13UK BROKER RATINGS SUMMARY: Peel Hunt Cuts Grafton After Warning
UK BROKER RATINGS SUMMARY: Peel Hunt Cuts Grafton After Warning
17 Oct 19 09:30TOP NEWS: AstraZeneca Breast Cancer Drug Granted US Priority Review
TOP NEWS: AstraZeneca Breast Cancer Drug Granted US Priority Review
17 Oct 19 08:17AstraZeneca breast cancer drug candidate clears FDA hurdle
(Sharecast News) - AstraZeneca, alongside its partner Daiichi Sankyo Company, announced on Thursday that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for trastuzumab deruxtecan, or DS-8201, and granted it 'Priority Review' status.
17 Oct 19 07:37AstraZeneca gets FDA priority review for experimental breast cancer drug
Oct 17 (Reuters) - Drugmaker AstraZeneca Plc said on Thursday its experimental breast cancer treatment will get a speedy review by the U.S. Food and Drug Administration, with a decision by the health regulator expected in the second quarter of ne...
17 Oct 19 07:29Tuesday broker round-up
(Sharecast News) - Ocado: JP Morgan downgrades to underweight with a target price of 1,050p.
15 Oct 19 12:47UK BROKER RATINGS SUMMARY: UBS Raises Whitbread To Buy From Neutral
UK BROKER RATINGS SUMMARY: UBS Raises Whitbread To Buy From Neutral
15 Oct 19 09:29UPDATE 1-FTSE falters as Brexit hopes lift pound; domestic stocks rejoice
* FTSE 100 down 0.3%, FTSE 250 up 0.8%* Brexit deal hopes lift sterling, hit exporters* Housebuilders, UK banks jump* WPP, Burberry fall after European rivals cut forecast* Dart Group climbs higher after hiking profit view (Adds news items, analyst ...
11 Oct 19 09:07UPDATE 2-Recharged hopes of Brexit deal, trade truce power UK shares
* FTSE 100, FTSE 250 up 0.3%* Mondi reverses course to close higher* Miners biggest boost to main index* FTSE 100 confirms "Death Cross" pattern (Adds company news items, updates share moves, changes analyst comments)By Muvija M and Shashwat Awasth...
10 Oct 19 09:40Wednesday broker round-up
(Sharecast News) - Volution Group: Peel Hunt upgrades to buy with a target price of 200p.
9 Oct 19 12:51Wellington Management Builds 5.9% Stake In Drugsmaker AstraZeneca
Wellington Management Builds 5.9% Stake In Drugsmaker AstraZeneca
4 Oct 19 15:22WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US
WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US
4 Oct 19 10:26FDA green lights AstraZeneca's asthma drug Fasenra for self-administration
Oct 4 (Reuters) - British drugmaker AstraZeneca said on Friday that the U.S. Food and Drug Administration (FDA) has approved self-administration of its asthma treatment Fasenra which uses a pre-filled, single-use auto-injector pen.The move is a bo...
4 Oct 19 08:06